Nanoparticles have demonstrated great potential for enhancing drug delivery. However, the low drug encapsulation efficiency at high drug-to-nanoparticle feeding ratios and minimal drug loading content in nanoparticle at any feeding ratios are major hurdles to their widespread applications. Here we report a robust eukaryotic cell-like hybrid nanoplatform (EukaCell) for encapsulation of theranostic agents (doxorubicin and indocyanine green). The EukaCell consists of a phospholipid membrane, a cytoskeleton-like mesoporous silica matrix and a nucleus-like fullerene core. At high drug-to-nanoparticle feeding ratios (for example, 1:0.5), the encapsulation efficiency and loading content can be improved by 58 and 21 times, respectively, compared with conventional silica nanoparticles. Moreover, release of the encapsulated drug can be precisely controlled via dosing near infrared laser irradiation. Ultimately, the ultra-high (up to ∼87%) loading content renders augmented anticancer capacity both in vitro and in vivo. Our EukaCell is valuable for drug delivery to fight against cancer and potentially other diseases.

中文翻译：

---

仿生混合纳米平台，用于封装和精确控制治疗药物的输送。[更正]。

纳米颗粒已显示出增强药物递送的巨大潜力。然而，在高的药物与纳米颗粒的进料比下，低的药物包封效率以及在任何进料比下的纳米粒子中最小的药物负载量是其广泛应用的主要障碍。在这里，我们报告一个强大的真核细胞样杂交纳米平台（EukaCell）用于囊体化治疗剂（阿霉素和吲哚菁绿）的封装。EukaCell由磷脂膜，细胞骨架状的中孔二氧化硅基质和核状的富勒烯核组成。在药物与纳米颗粒的高进料比（例如1：0.5）下，与传统的二氧化硅纳米颗粒相比，包封效率和负载量可以分别提高58倍和21倍。而且，可以通过剂量近红外激光辐射来精确控制包封药物的释放。最终，超高（高达〜87％）的负载量使体内和体外的抗癌能力增强。我们的EukaCell可用于药物输送，以抗击癌症和其他潜在疾病。